

Financial Results of the 3rd Quarter for Fiscal Year Ending June 2026

May 15, 2026

(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

*Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.*

FYE June 2026 Q3 YTD Main Points -1

Net sales 108,366 Mil.Yen <Year-on-year +18.0%>
Progressed favorably both Medical and Device Division
due to expanding demand, etc.

- **Medical Division ~Progressed favorably in both Cardiovascular and Non-cardiovascular~**
 - Cardiovascular field: Increased mainly in PCI GW and Penetration catheter in all regions
 - Non-Cardiovascular field: Peripheral (all regions, including U.S.) and Abdominal (all regions) increased in all overseas regions
- **Device Division ~ Increased in both Medical and Industrial Components ~**
 - Increased both Medical and Industrial Components due to the consolidation of Nitta Mold as a subsidiary
 - Medical Components business: Increased in transactions of cardiovascular inspection catheter components for the U.S. and cardiovascular ultrasound catheter components for Asian markets
 - Industrial Components business: Increased in overseas leisure-related transactions
- **Impact of exchange rate fluctuation (Yen depreciation) (+3,100 Mil. Yen)**

Exchange rate (Unit : JPY)	US\$	EURO	CNY	BAHT
FYE June 2026 Q3 YTD	152.73	178.34	21.64	4.77
FYE June 2025 Q3 YTD	151.48	162.50	20.98	4.42

FYE June 2026 Q3 YTD Main Points -2

Operating profit 37,414 Mil. Yen <YoY +45.5%>

Operating profit increased significantly due to sales growth and an improvement in the gross profit margin

■ **Gross profit: 76,788 Mil.Yen < YoY +23.3% >**

- Increased due to sales growth and an improvement in the gross profit margin (67.8% → 70.9%) driven by productivity improvement
- The impact of increased cost of sales due to U.S. tariffs YoY +823 Mil. Yen

■ **Operating profit: 37,414 Mil.Yen <YoY +45.5% >**

- SGA expenses were overall restrained (YoY +2,825 Mil. Yen, increase rate +7.7%)
- Increased in sales-related expenses due to strengthen promotional activities mainly in the U.S.
- Increased in R&D expenses (9,213 Mil.Yen) (YoY +524 Mil.Yen, R&D-to-sales ratio 8.5 %)
- Increased in personnel expenses due to expanded hiring
- Increased due to the consolidation of Nitta Mold as a subsidiary
- Decreased in goodwill amortization, etc. (YoY -1,161 Mil. Yen)

■ **Ordinary profit: 37,207 Mil.Yen <YoY +45.4% >**

- Non-operating income: Decreased in subsidy income (YoY -688 Mil.Yen)
- Non-operating expenses: Decreased in foreign exchange losses (YoY -578 Mil.Yen)

■ **Net income attributable to parent company shareholders: 26,657 Mil.Yen <YoY +204.2% >**

- Extraordinary income: Increased gain on sale of investment securities (YoY +1,504 Mil.Yen)
- Extraordinary loss: Decreased in impairment losses (YoY -9,300 Mil. Yen), etc.

Highlights Year-on-Year

	FYE June 2025 Q3 YTD		FYE June 2026 Q3 YTD			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)
Net sales	91,815	100.0	108,366	100.0	+16,551	+18.0
Gross Profit	62,263	67.8	76,788	70.9	+14,524	+23.3
Operating profit	25,715	28.0	37,414	34.5	+11,698	+45.5
Ordinary profit	25,594	27.9	37,207	34.3	+11,613	+45.4
Net income attributable to parent company shareholders	8,763	9.5	26,657	24.6	+17,894	+204.2
EPS (yen)	32.26	–	100.13	–	+67.87	+210.4

(Reference) At the same exchange rate as the previous year			
Amount (Mil.Yen)	Ratio (%)	YoY	
		Changes (Mil.Yen)	Changes (%)
105,266	100.0	+13,450	+14.6
74,662	70.9[*]	+12,398	+19.9
35,897	34.1	+10,182	+39.6

*: Gross profit margin after adjusting for forex impacts other than those related to unrealized profit

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2026 Q3 YTD	152.73	178.34	21.64	4.77
FYE June 2025 Q3 YTD	151.48	162.50	20.98	4.42

Sales by Segment Year-on-year


	FYE June 2025 Q3 YTD		FYE June 2026 Q3 YTD			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Medical	82,721	90.1	94,766	87.4	+12,045	+14.6
Device	9,094	9.9	13,600	12.6	+4,505	+49.5
Total amount	91,815	100.0	108,366	100.0	+16,551	+18.0

(Reference)


Medical Field	88,740	96.7	103,417	95.4	+14,676	+16.5
Device Field	3,074	3.3	4,948	4.6	+1,874	+60.9

Earnings Performance by Segment

Net sales




Operating profit




Attribution Analysis of Operating profit – 1

(Exchange Rate Fluctuations Included)



Attribution Analysis of Operating profit – 2


(Exchange Rate Fluctuations Excluded)



Per Segment by Medical Division (by Geography-1)

[Net sales (YoY)] ~ Increased in all regions, overall remained steady~

- **Japan** : Increased in Non-cardiovascular field
 - Cardiovascular field : Although PCI GW and Penetration catheter increased, products for inspection decreased(*), resulting in flat trend
 - Non-cardiovascular field : Strong sales of purchased products in Peripheral vascular (Penumbra) and Peripheral guidewires
- **Overseas** : Increased across all regions, with positive effects from exchange rate fluctuations
 - **US**: Progressed well in brand products business
 - Cardiovascular field : Increased in PCI GW and Penetration catheter
 - Non-cardiovascular field : Increased in Abdominal and Peripheral vascular
 - **Europe**: Progressed favorably due to increases in both direct sales and distributor transactions in Western Europe, in addition to bolstering by favorable forex rate
 - Cardiovascular field : Increased in PCI GW and Penetration catheter, while decreased in Guiding catheter*
 - Non-cardiovascular : Increased in various areas such as Peripheral vascular, Abdominal vascular and Neurovascular products.
 - **China**: Inventory replenishment (forward shipment) due to sales network changes occurred in both previous and current terms, excluding this impact, remained steady
 - Cardiovascular field : PCI GW progressed well while balloon catheter decreased due to termination of transactions
 - Non-cardiovascular field : Increased in Abdominal and Peripheral vascular products
 - **Other**: Progressed well mainly in Asia
 - Cardiovascular field : Increased in PCI GW and Penetration catheters mainly in Asia
 - Non-cardiovascular field : Increased Peripheral, Abdominal vascular and Neurovascular products mainly in Asia



[Operating profit] Operating profit increased in proportion to sales

(* Discontinuation of low-profit products)


Per Segment by Medical Division (by Geography-2)

(Mil. Yen)		FYE June 2025 Q3 YTD	FYE June 2026 Q3 YTD	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	151.48	152.73	+1.25	+0.8
	EURO	162.50	178.34	+15.84	+9.7
	CNY	20.98	21.64	+0.66	+3.1
Total sales		82,721	94,766	+12,045	+14.6
Japan		11,967	12,594	+626	+5.2
Overseas		70,753	82,171	+11,418	+16.1
US		17,033	19,181	+2,147	+12.6
Europe		18,071	21,346	+3,275	+18.1
China		23,101	28,092	+4,991	+21.6
Other		12,547	13,551	+1,004	+8.0
Operating profit		27,416	36,132	+8,716	+31.8

Per Segment by Medical Division (by Treatment-1)

[Net sales (YoY)]

(Mil. Yen)



Cardiovascular

- Japan : Although PCI GW and Penetration catheter increased, products for inspection decreased(*), resulting flat trend
- Overseas : Increased across all regions, with positive effects from exchange rate fluctuations
 - U.S.: Increased in PCI GW and Penetration catheter
 - Europe: Increased in PCI GW and Penetration catheter, and decreased in Guiding catheters(*)
 - China: PCI GW progressed well while balloon catheter decreased due to termination of transactions
 - Other: Increased in PCI GW and Penetration catheters mainly in Asia

(* Discontinuation of low-profit products)

Non-Cardiovascular

- Japan : Strong sales of purchased products in Peripheral vascular (Penumbra) and Peripheral guidewires
- Overseas : Increased in Peripheral vascular and Abdominal vascular across all regions
 - U.S.: Increased in Abdominal and Peripheral vascular
 - Europe :Increased in each areas such as Peripheral, Abdominal vascular and Neurovascular
 - China : Increased in Abdominal vascular and Peripheral vascular products
 - Other : Increased in Peripheral, Abdominal vascular and Neurovascular products mainly in Asia


OEM

- Japan : Decreased transactions due to business partner trends
- Overseas : Although increased in contract development transactions in U.S., decreased OEM transactions in Asia

Per Segment by Medical Division (by Treatment-2)

(Mil. Yen)		FYE June 2025 Q3 YTD	FYE June 2026 Q3 YTD	YoY	
				Changes	Changes(%)
Exchange rate (Yen)	USD	151.48	152.73	+1.25	+0.8
	EURO	162.50	178.34	+15.84	+9.7
	CNY	20.98	21.64	+0.66	+3.1
Total sales		82,721	94,766	+12,045	+14.6
	Japan	11,967	12,594	+626	+5.2
	Overseas	70,753	82,171	+11,418	+16.1
Cardiovascular		62,649	71,337	+8,687	+13.9
	Japan	6,441	6,470	+29	+0.5
	Overseas	56,208	64,866	+8,658	+15.4
Non-Cardiovascular		14,174	17,673	+3,499	+24.7
	Japan	4,230	4,942	+711	+16.8
	Overseas	9,943	12,731	+2,788	+28.0
OEM		5,897	5,754	-142	-2.4
	Japan	1,295	1,181	-114	-8.8
	Overseas	4,601	4,573	-28	-0.6

Per Segment by Device Division-1



【Net sales (YoY)】

Increased in both Medical components and Industrial components
Even excluding the consolidation of Nitta Mold as a subsidiary
(+2,062 Mil. Yen) , results remained strong

Medical Component

- Japan : Increased due to the consolidation of Nitta Mold as a subsidiary
- Overseas : Increased transactions of cardiovascular inspection catheter components for the U.S. and transactions of cardiovascular ultrasound catheter components for Asian markets

Industrial Component

- Japan : Increased due to the consolidation of Nitta Mold as a subsidiary
- Overseas : Increased leisure-related transactions and due to the consolidation of Nitta Mold as a subsidiary

【Operating profit】

Increased due to growth in external sales and intersegment transaction

Per Segment by Device Division-2

(Mil. Yen)		FYE June 2025 Q3 YTD	FYE June 2026 Q3 YTD	(Increase due to the consolidation of Nitta Mold as a subsidiary) A	YoY		YoY excluding the impact of A	
					Changes	Changes (%)	Changes	Changes (%)
Exchange rate (Yen)	USD	151.48	152.73	-	+1.25	+0.8	-	-
Total sales		9,094	13,600	2,062	+4,505	+49.5	+2,443	+26.9
Japan		2,084	2,801	858	+716	+34.4	-141	-6.8
Overseas		7,009	10,798	1,204	+3,788	+54.1	+2,584	+36.9
Medical Components		6,019	8,651	593	+2,631	+43.7	+2,038	+33.9
Japan		816	1,313	547	+497	+60.9	-50	-6.2
Overseas		5,203	7,337	46	+2,134	+41.0	+2,088	+40.1
Industrial Components		3,074	4,948	1,469	+1,874	+60.9	+404	+13.2
Japan		1,268	1,487	310	+219	+17.3	-90	-7.2
Overseas		1,806	3,461	1,158	+1,654	+91.6	+495	+27.4
Operating profit		3,856	7,274	295	+3,417	+88.6	+3,122	+81.0
(Reference) Intersegment sales		10,787	12,652	-	+1,865	+17.3	+1,865	+17.3


Reference: P/L

	FYE June 2025 Q3 YTD		FYE June 2026 Q3 YTD			
	Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Net sales	91,815	100.0	108,366	100.0	+16,551	•Both Medical Division and Device Division performed well
Cost of sales	29,551	32.2	31,578	29.1	+2,026	
Gross profit	62,263	67.8	76,788	70.9	+14,524	•Increase in proportion to increasing sales and gross profit margin
SGA	36,548	39.8	39,374	36.3	+2,825	•Increase in expenses related to sales, R&D and personnel
Operating profit	25,715	28.0	37,414	34.5	+11,698	
Non-operating income	1,236	1.3	529	0.5	-707	•Decrease in subsidy income
Non-operating expense	1,357	1.5	735	0.7	-622	•Decrease in foreign exchange losses
Ordinary profit	25,594	27.9	37,207	34.3	+11,613	
Extraordinary income	123	0.1	1,527	1.4	+1,404	•Increase in gain on sale of investment securities
Extraordinary loss	10,730	11.7	946	0.9	-9,783	•Decrease in impairment losses, etc.
Net income attributable to parent company shareholders	8,763	9.5	26,657	24.6	+17,894	
Comprehensive income	5,563	6.1	32,866	30.3	+27,303	

Reference: B/S

		FYE June 2025 Results		FYE June 2026 Q3 YTD			
		Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Assets	Current assets	103,359	53.5	114,543	56.2	+11,183	Cash and deposits +5,596 Notes and accounts receivable-trade +3,417 Inventories +2,090
	Fixed assets	89,827	46.5	89,186	43.8	-640	Tangible fixed assets +1,152 Investments and other assets -1,356
Total assets		193,187	100.0	203,730	100.0	+10,542	
Liabilities	Current liabilities	27,856	14.4	22,732	11.2	-5,124	Notes and accounts payable-trade +1,028 Provision for bonuses -1,249 Other -5,415
	Fixed liabilities	13,976	7.2	13,838	6.8	-138	Long-term borrowings -1,772 Other +1,214
Total liabilities		41,833	21.7	36,570	18.0	-5,262	
Total net assets		151,354	78.3	167,159	82.0	+15,805	Retained earnings +8,069 Foreign currency translation adjustment +6,476 Treasury shares +4,434 Capital surplus -2,907
Total liabilities & net assets		193,187	100.0	203,730	100.0	+10,542	

Reference: C/F



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

[IR contact]

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-56-1851

URL <https://www.asahi-intecc.co.jp/en>